<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benzodiazepine and nonbenzodiazepine hypnotic pharmacokinetics</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benzodiazepine and nonbenzodiazepine hypnotic pharmacokinetics</h1>
<div class="graphic"><div class="figure"><div class="ttl">Benzodiazepine and nonbenzodiazepine hypnotic pharmacokinetics</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Generic name</td> <td class="subtitle1">Trade name</td> <td class="subtitle1">Usual single adult dose (oral)</td> <td class="subtitle1">Oral peak (hours)</td> <td class="subtitle1">Half-life (hours) parent</td> <td class="subtitle1">Metabolite activity<sup>*</sup></td> <td class="subtitle1">CYP3A4 interactions<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="7">Benzodiazepines</td> </tr> <tr> <td class="subtitle3_left" colspan="7">Short-acting (&lt;12 hours)</td> </tr> <tr> <td class="indent2">Midazolam</td> <td>Versed</td> <td>0.25 to 0.5 mg/kg; maximum 20 mg (oral formulation not used in adults; dosing is for pediatric sedation)</td> <td>&lt;1 to 2.5</td> <td>1.5 to 3</td> <td>Active</td> <td>Yes</td> </tr> <tr> <td class="indent2">Triazolam</td> <td>Halcion</td> <td>0.125 to 0.25 mg</td> <td>0.7 to 2</td> <td>2 to 3</td> <td>Inactive</td> <td>Yes</td> </tr> <tr> <td class="subtitle3_left" colspan="7">Intermediate-acting (12 to 24 hours)</td> </tr> <tr> <td class="indent2">Alprazolam</td> <td>Xanax</td> <td>0.25 to 0.5 mg</td> <td>1 to 2</td> <td>6 to 27</td> <td>Inactive</td> <td>Yes</td> </tr> <tr> <td class="indent2">Bromazepam<sup>Δ</sup></td> <td>Lexotan, Lexotanil</td> <td>2 to 6 mg</td> <td>1 to 2</td> <td>8 to 20</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class="indent2">Estazolam</td> <td>Prosom</td> <td>0.5 to 2 mg</td> <td>0.5 to 6</td> <td>10 to 24</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class="indent2">Etizolam<sup>Δ</sup><sup>◊</sup></td> <td>Depas, Etilaam, Etizola</td> <td>0.5 to 1 mg</td> <td>0.5 to 3</td> <td>3 to 6</td> <td>Active (half-life 8 hours)</td> <td>Yes</td> </tr> <tr> <td class="indent2">Lorazepam</td> <td>Ativan</td> <td>0.5 to 3 mg</td> <td>2 to 4</td> <td>10 to 20</td> <td>Inactive</td> <td>No</td> </tr> <tr> <td class="indent2">Oxazepam</td> <td>Serax</td> <td>10 to 30 mg</td> <td>2 to 4</td> <td>5 to 20</td> <td>Inactive</td> <td>No</td> </tr> <tr> <td class="indent2">Temazepam</td> <td>Restoril</td> <td>7.5 to 30 mg</td> <td>1 to 2</td> <td>3 to 19</td> <td>Inactive</td> <td>No</td> </tr> <tr> <td class="subtitle3_left" colspan="7">Long-acting (&gt;24 hours)</td> </tr> <tr> <td class="indent2">Chlordiazepoxide</td> <td>Librium</td> <td>5 to 25 mg</td> <td>0.5 to 4</td> <td>5 to 30</td> <td>Active</td> <td>Yes (CYP3A4 inhibitors); limited (CYP3A4 inducers)</td> </tr> <tr> <td class="indent2">Clobazam</td> <td>Onfi</td> <td>10 to 20 mg</td> <td>0.5 to 4</td> <td>36 to 42</td> <td>Active (half-life 71 to 82 hours)</td> <td>Limited (interacts via CYP2C19)</td> </tr> <tr> <td class="indent2">Clonazepam</td> <td>Klonopin</td> <td>0.25 to 0.5 mg</td> <td>1 to 2</td> <td>18 to 50</td> <td>Inactive</td> <td>Limited</td> </tr> <tr> <td class="indent2">Clorazepate</td> <td>Tranxene</td> <td>7.5 to 15 mg</td> <td>1 to 2</td> <td>Prodrug</td> <td>Active (half-life 20 to 160 hours)</td> <td>Limited</td> </tr> <tr> <td class="indent2">Diazepam</td> <td>Valium</td> <td>2 to 10 mg</td> <td>0.5 to 1</td> <td>20 to 50</td> <td>Active</td> <td>Yes (also interacts via CYP2C19)</td> </tr> <tr> <td class="indent2">Flunitrazepam<sup>Δ</sup></td> <td>Rohypnol</td> <td>0.5 to 2 mg</td> <td>1 to 2</td> <td>16 to 35</td> <td>Active</td> <td>Limited</td> </tr> <tr> <td class="indent2">Flurazepam</td> <td>Dalmane</td> <td>15 to 30 mg</td> <td>0.5 to 1</td> <td>2 to 4</td> <td>Active</td> <td>Limited</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Nonbenzodiazepine hypnotics</td> </tr> <tr> <td class="indent1">Eszopiclone</td> <td>Lunesta</td> <td>1 to 3 mg</td> <td>1</td> <td>6 to 9</td> <td>Active (less than parent)</td> <td>Yes</td> </tr> <tr> <td class="indent1">Zaleplon</td> <td>Sonata</td> <td>5 to 15 mg</td> <td>1</td> <td>1</td> <td>Inactive</td> <td>Yes (CYP3A4 inducers); limited (CYP3A4 inhibitors)</td> </tr> <tr> <td class="indent1">Zolpidem</td> <td>Ambien, Edluar, Zolpimist</td> <td>5 to 10 mg</td> <td>1 to 2</td> <td>1.5 to 8.4</td> <td>Inactive</td> <td>Yes</td> </tr> <tr> <td class="indent1">Zopiclone<sup>Δ</sup></td> <td>Imovane</td> <td>3.75 to 7.5 mg</td> <td>&lt;2</td> <td>5 to 7</td> <td>Active (less than parent)</td> <td>Yes</td> </tr> </tbody></table></div><div class="graphic_lgnd">Duration of action of compounds having active metabolite(s) is significantly greater than predicted by half-life of parent.</div><div class="graphic_footnotes"><p>* Half-life of active metabolite(s) may exceed 50-100 hours.</p>
<p>¶ A list of strong and moderate CYP3A inhibitors and inducers is provided in a separate table within UpToDate. When initiating or altering drug therapy, use of a drug interactions database such as the <a href="https://www.uptodate.com/drug-interactions">drug interactions program</a> is advised.</p>
<p>Δ Not available in United States.</p>
    
    ◊ Etizolam is a thienodiazepine derivative and benzodiazepine receptor agonist; its pharmacologic effects are similar to those of classical benzodiazepines <span class="nowrap_whitespace">(eg, diazepam).<sup>[1]</sup></span></div><div class="graphic_reference">Reference:
    <ol>
<li>Etizolam. World Health Organization. Available at: https://www.who.int/medicines/access/controlled-substances/5.7_Etizolam_PreRev.pdf (Accessed on February 24, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 69184 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
